Liz Szabo, Kaiser Health News
A growing number of patients and doctors are concerned about overtreatment, which is rampant across the healthcare system.
Total costs of Kymriah and 21 similar drugs in development - CAR T-cell therapies - will reach $1 million or more per patient, according to leading cancer experts.
Novartis officials said it is working with 20 hospitals to provide Kymriah within a month.
Novartis hasn't announced their final cost but the 'quantum leap' price tag expected has implications for reimbursement and insurance premiums overall.